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Summary
The majority of transcatheter aortic valve implantations,
structural heart procedures and the newly developed tran-
scatheter mitral valve repair and replacement are tradition-
ally performed either through a transfemoral or a trans-
apical access site, depending on the presence of severe
peripheral vascular disease or anatomic limitations. The
transapical approach, which carries specific advantages re-
lated to its antegrade nature and the short distance between
the introduction site and the cardiac target, is traditionally
performed through a left anterolateral mini-thoracotomy
and requires rib retractors, soft tissue retractors and rein-
forced apical sutures to secure, at first, the left ventricular
apex for the introduction of the stent-valve delivery sys-
tems and then to seal the access site at the end of the pro-
cedure.
However, despite the advent of low-profile apical sheaths
and newly designed delivery systems, the apical approach
represents a challenge for the surgeon, as it has the risk
of apical tear, life-threatening apical bleeding, myocardial
damage, coronary damage and infections. Last but not
least, the use of large-calibre stent-valve delivery systems
and devices through standard mini-thoracotomies com-
promises any attempt to perform transapical transcatheter
structural heart procedures entirely percutaneously, as hap-
pens with the transfemoral access site, or via a thoraco-
scopic or a miniaturised video-assisted percutaneous tech-
nique.
During the past few years, prototypes of apical access and
closure devices for transapical heart valve procedures have
been developed and tested to make this standardised suc-
cessful procedure easier. Some of them represent an im-
portant step towards the development of truly percutaneous
transcatheter transapical heart valve procedures in the clin-
ical setting.
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Introduction
During recent years, transcatheter heart valve procedures
and percutaneous transcatheter procedures for structural
heart diseases have emerged as excellent alternatives to
standard medical therapy and to standard open-heart sur-
gery for inoperable patients or patents at high risk for sur-
gery, or in redo procedures [1, 2]. In recently published
clinical papers, the well-established and standardised tran-
scatheter aortic valve implantation (TAVI) technique was
confirmed to be associated with very good hospital out-
comes and mid-term clinical results, with noninferiority
compared with standard aortic valve surgery in a prospect-
ive randomised clinical trial including elderly patients with
very high surgical risk profiles [1–3].
With regard to the upcoming transcatheter mitral valve pro-
cedures, mitral valve replacement (with Edwards SapienTM
THV in calcified native mitral valves, and Neovasc TiaraTM
and Edwards FortisTM in regurgitant native mitral valves),
the valve-in-valve technique for degenerated biopros-
theses, and promising mitral valve repairs (Abbott Vascular
MitraClipTM, NeochordTM system) have already shown
good preliminary clinical results and will probably became,
in the near future, valid minimally invasive alternatives to
standard open-heart surgery in selected patients [4, 5].
Structural heart diseases such as mitral or aortic paravalv-
ular leaks and left ventricular pseudoaneurysms can also
be addressed percutaneously in patients at high risk for
surgery: teams of interventional cardiologists have already
employed muscular ventricular septal defect occluders,
AmplatzerTM ductal occluders and AmplatzerTM vascular
plug II occluders (off-label use) to treat intracardiac dis-
eases successfully and fully percutaneously [6, 7].
Concerning the preferred access site, most of these innov-
ative transcatheter procedures are easily performed percu-
taneously through peripheral arteries or veins, but in the
case of severe peripheral vascular disease or patients with
unfavourable thoracoabdominal vascular anatomy the left
ventricular apical access site reached through a left antero-
lateral mini-thoracotomy (7–10 cm) at the fifth intercostal
space remains a valid alternative, with well-known technic-
al advantages as a result of the very short distance between
the apex and the intracardiac anatomical structures. Never-
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theless, despite the advent of low-profile delivery systems,
the left ventricular apical access site remains a challenge
for the surgeon when large-size introducer sheaths are em-
ployed (risk of intraoperative complications) and the stand-
ard technique still limits the development of closed-chest
transapical transcatheter valve procedures such as video-
assisted thoracoscopic TAVI or truly percutaneous transap-
ical TAVI [8].
Described here are new devices engineered for apical ac-
cess and closure that have been developed and tested dur-
ing recent years in order to support, simplify and standard-
ise minimally invasive transapical heart valve procedures:
the Apica™ ASC device (Apica Cardiovascular Limited,
Galway, Ireland) CE-marked in August 2013, the Cardi-
oClose™ device (Entourage Medical Technologies, CA,
USA), the CardiApex™ device (Cardiapex Ltd, Or Akiva,
Israel), the Permaseal™ device (Micro International
Device, PA, USA), and the Safex™ device (Comed,
Bolsward, The Netherlands) [9–16].
Transapical access and closure
devices
Most of the following apical access and closure devices
are still under evaluation in feasibility tests in an animal
setting, or have just entered pre-commercial clinical trials
with preliminary tests in humans. Only one device has ac-
quired, in 2013, the European Union mark (CE mark) for
commercial and clinical use in Europe.
The ApicaTM device
The ApicaTM system (Apica Cardiovascular Limited, Gal-
way, Ireland) is, at the moment, the only commercially
available apical access and closure device and it received
the CE-mark in 2013. It is a closure system of three parts:
the introducer, a left ventricular coil and the closure cap
(fig. 1A and B). The introducer and the coil are one part
and are surgically placed in the left ventricular apex over a
stiff wire and through a standard anterolateral mini-thora-
Figure 1
(A) and (B) The ApicaTM access and closure device is composed of
three parts: the introducer, the coil and the cap (reprinted with
permission from ThoratecTM Corporation). (C) and (D) The
CardiApexTM device is an apical delivery and plug allowing for full-
percutaneous transapical valve procedures (reprinted with
permission from Benad Goldwasser, former CEO of Cardiapex
Ltd.).
cotomy. The fixation system consists of a screw-like distal
part of the coil that is inserted in the left ventricular
myocardium by rotating the system. Through the introdu-
cer, the transcatheter valve procedure is performed, while
the haemostasis is guaranteed by the coil screwed in the
myocardium. Following the procedure, when the stent-
valve delivery system is removed, the closure cap is placed
into the introducer and fixed to the coil for final sealing of
the apical access site. Then the introducer is disconnected.
At the moment, the current version of the ApicaTM device
allows transapical valve procedures without rib-spreading
but it does not support fully percutaneous transapical TAVI
[10–12].
The CardioClose™ device
CardioClose™ (Entourage Medical Technology, Menlo
Park, CA, USA) is a device that mimics a surgical purse-
string suture in the cardiac apex and is placed through a
standard surgical mini-thoracotomy for cardiac exposure.
The device is composed of two double helical needles with
sutures, and small endocardial nitinol anchors. The device
is placed, over the wire, against the apex and the two hel-
ical needles with sutures are screwed into the myocardium
until the nitinol anchors self-deploy in the ventricular cav-
ity. The external ends of the sutures are controlled by spe-
cific suture-locking buttons that can be manually adjusted
at the end of the transcatheter procedure: after the valve
implantation and after the removal of the delivery system,
the two sutures of the CardioClose™ are tightened by lock-
ing the two buttons. At the moment, the device is being
tested in a clinical setting after acute and chronic animal
tests demonstrated promising preliminary results.
The CardiApex™ device
The CardiApex™ device (Cardiapex Ltd, Or Akiva, Israel)
was designed to be employed in truly percutaneous trans-
apical heart valve procedures and consists of two main
parts: an apical plug and a catheter with introducer sheath
(fig. 1C and D). It is a sutureless apical closure device not
requiring a standard mini-thoracotomy. Through a trans-
femoral arterial puncture, a catheter equipped with a punc-
turing needle is retrogradely advanced into the left vent-
ricle: the ventricular apex is punctured from inside to out-
side the pericardium, and a stiff wire is advanced outside
the pericardium. At the same time, a 10-mm trocar is
placed, percutaneously, into the sixth intercostal space and
the stiff wire is snared and used to convey the CardiApexTM
sheath into the pericardium and through the left ventricular
apex. Two balloons surrounding the sheath are inflated in-
side and outside the ventricle to guarantee haemostasis and
to allow for the stent-valve delivery device to be advanced
through the sheath. Once the transapical procedure is com-
plete, an umbrella-like plug is deployed at the apex. Pre-
liminary feasibility tests in an animal setting have been per-
formed and clinical data are pending.
The Permaseal™ device
Permaseal™ (Micro Interventional Device, Newton, PA,
USA) is a device that implants eight biocompatible V-
stays at the apex of the left ventricle for apical sealing
(fig. 2A and B). The device still requires a left mini-thora-
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cotomy and is not designed to support percutaneous closed-
chest transapical procedures. After wire access is obtained,
the gun-shaped delivery system is placed, over the wire,
against the epicardium at the level of the cardiac apex.
Then the system is manually activated and eight polypro-
pylene anchors with a 2-0 braided polyester suture perfor-
ate the myocardium and create a series of V-stays. This
creates a channel in which stent-valve delivery systems
are placed after the gun-shaped PermasealTM delivery sys-
tem has been removed: transapical valve procedures can be
easily performed without active bleeding. Following valve
deployment, all catheters and wires are removed and the
device closes spontaneously by pulling the pre-tied sutures
in order to seal the apical access site. The PermasealTM has
entered the clinical test phase in a human setting to receive
CE mark approval for commercial use in Europe (STASIS
multicentre study enrolling, at this time, 34 patients).
The SafexTM device
The new apical closure device from Comed (Comed,
Bolsward, The Netherlands) has recently passed prelimin-
ary tests of safety and feasibility in an acute animal model.
The SafexTM is a self-expanding, self-anchoring, self-seal-
ing modified ventricular septal defect occluder and is made
of woven nitinol wires into two self-expandable round re-
tention disks with a connecting extendable and flexible
waist 10 mm in diameter (fig. 2C). The inner and outer
disks present two membranes made of expanded polytet-
rafluoroethylene (ePTFE) that guarantee mechanical occlu-
sion of large-size apical access sites, and guarantee blood
clotting for long-term haemostasis. Thanks to its adaptab-
ility, the device is expected to occlude apical access sites
ranging from 20 Fr to 35 Fr, and is specifically designed for
closed-chest percutaneous transapical valve procedures. In
fact, the SafexTM apical closure device is at first connected
Figure 2
(A) The PermasealTM device is made of eight polypropylene V-stays
inserted in the left ventricular apex. (B) The gun-shaped
PermasealTM delivery system (Source: courtesy of Micro
Interventional Devices). (C) The SafexTM is a self-expandable, self-
anchoring and self-sealing flexible device. (D) Surgical view of the
SafexTM device.
to its wire, then folded and inserted into a 10 Fr delivery
system. This delivery system is placed into the left vent-
ricle through the large-size transapical introducer sheath
used for the placement of the stent-valve. Then the plug is
deployed with a simple two-step manoeuvre: the inner disk
is deployed first, the systems are pulled back towards the
apex and then the outer disk is deployed while the sheaths
are pulled out (fig. 2D) [13–16]. Haemodynamic tests and
chronic animal tests are planned.
Conclusion
Transapical access through the apex of the left ventricle is
a safe approach with a low rate of access-site related com-
plications, and it carries the advantage of a short pathway
between the introduction site and the intracardiac target.
Moreover, apical access facilitates a wide range of intrac-
ardiac procedures allowing for the use of relatively large
size apical sheaths carrying all sorts of biological valves
and devices.
However, the standard surgical apical approach through a
left mini-thoracotomy limits the development of true per-
cutaneous or video-assisted thoracoscopic apical proced-
ures and is still perceived as a more invasive technical/
surgical procedure compared with the less invasive percu-
taneous transfemoral access site. Therefore, the develop-
ment of new apical access and closure devices represents
an important step towards further development of this tech-
nique: it will simplify and standardise the transapical tran-
scatheter technique and it will allow for the development
of less invasive transapical valve procedures. Other import-
ant advantages will be the flattening of the initial learning
curve and the introduction of transapical transcatheter heart
valve procedures in low-volume cardiac centres not very
familiar with this useful approach. However, at the moment
only one device is available for commercial use in Europe,
and it still requires a left anterior mini-thoracotomy.
Interestingly, among the cited closure devices the
CardiApexTM, and the SafexTM device are specifically de-
signed and developed to work in a closed-chest truly percu-
taneous transapical setting. If clinical human tests confirm
the successful results of the preliminary animal tests, this
noninvasive percutaneous transapical approach will prob-
ably represent a new milestone in the era of transcatheter
heart valve procedures.
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Figures (large format)
Figure 1
(A) and (B) The ApicaTM access and closure device is composed of three parts: the introducer, the coil and the cap (Source: courtesy of
ThoratecTM Corporation). (C) and (D) The CardiApexTM device is an apical plug allowing for full-percutaneous transapical valve procedures
(Source: courtesy of Professor Hendrik Treede, University Heart Center Hamburg, Germany).
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Figure 2
(A) The PermasealTM device is made of eight polypropylene V-stays inserted in the left ventricular apex. (B) The gun-shaped PermasealTM
delivery system (Source: courtesy of Micro Interventional Devices). (C) The SafexTM is a self-expandable, self-anchoring and self-sealing flexible
device. (D) Surgical view of the SafexTM device.
Review article: Current opinion Swiss Med Wkly. 2016;146:w14237
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 6 of 6
